120 related articles for article (PubMed ID: 35017140)
1. Primary Enteric Adenocarcinoma Lung with Mesenchymal Epithelial Transition Factor Amplification: A Case Report.
Shukla S; Pandey RK; Husain N; Srivastava A
Gulf J Oncolog; 2021 May; 1(36):76-78. PubMed ID: 35017140
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases.
Wang CX; Liu B; Wang YF; Zhang RS; Yu B; Lu ZF; Shi QL; Zhou XJ
Int J Clin Exp Pathol; 2014; 7(3):1266-74. PubMed ID: 24696747
[TBL] [Abstract][Full Text] [Related]
3. Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry.
Zhang J; Xiang C; Han Y; Teng H; Li X; Shao J; Zhu L; Han-Zhang H; Ye J; Yu K
J Cancer Res Clin Oncol; 2019 Jan; 145(1):269-279. PubMed ID: 30415301
[TBL] [Abstract][Full Text] [Related]
4. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma.
Okada F; Takeda M; Fujii T; Uchiyama T; Sasaki S; Matsuoka M; Nitta Y; Terada C; Maebo K; Morita K; Ishida E; Sawabata N; Ohbayashi C
J Clin Pathol; 2024 Jan; 77(2):111-115. PubMed ID: 36456172
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological, radiographic, and oncogenic features of primary pulmonary enteric adenocarcinoma in comparison with invasive adenocarcinoma in resection specimens.
Zhao L; Huang S; Liu J; Zhao J; Li Q; Wang HQ
Medicine (Baltimore); 2017 Sep; 96(39):e8153. PubMed ID: 28953659
[TBL] [Abstract][Full Text] [Related]
7. A pulmonary enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S mutation: Case report and review.
Xu X; Chen D; Wu X; Wang Q
Front Oncol; 2022; 12():988625. PubMed ID: 36212391
[TBL] [Abstract][Full Text] [Related]
8. Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.
Zuo Y; Zhong J; Bai H; Xu B; Wang Z; Li W; Chen Y; Jin S; Wang S; Wang X; Wan R; Xu J; Fei K; Han J; Yang Z; Bao H; Shao Y; Ying J; Song Q; Duan J; Wang J
EBioMedicine; 2022 Aug; 82():104165. PubMed ID: 35901658
[TBL] [Abstract][Full Text] [Related]
9. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
Yeung SF; Tong JHM; Law PPW; Chung LY; Lung RWM; Tong CYK; Chow C; Chan AWH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2015 Sep; 10(9):1292-1300. PubMed ID: 26098749
[TBL] [Abstract][Full Text] [Related]
10. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
11. ROS-1 re-arrangements and c-MET amplifications in adenocarcinoma lung: A tertiary care center study from North India.
Shukla S; Pandey RK; Kant S; Garg R; Husain N
Indian J Pathol Microbiol; 2019; 62(3):433-436. PubMed ID: 31361233
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary enteric adenocarcinoma.
Gong J; Fan Y; Lu H
Transl Oncol; 2021 Aug; 14(8):101123. PubMed ID: 34000642
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy.
Garajová I; Funel N; Fiorentino M; Agostini V; Ferracin M; Negrini M; Frassineti GL; Gavelli G; Frampton AE; Biasco G; Giovannetti E
Clin Epigenetics; 2015; 7():129. PubMed ID: 26677401
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary Enteric Adenocarcinoma Harboring a BRAF G469V Mutation.
Shimizu D; Yamamoto H; Shien K; Taniguchi K; Miyoshi K; Namba K; Mesaki K; Sugimoto S; Soh J; Yamane M; Toyooka S
Acta Med Okayama; 2021 Dec; 75(6):759-762. PubMed ID: 34955547
[TBL] [Abstract][Full Text] [Related]
15. Genetic mutation profiles and immune microenvironment analysis of pulmonary enteric adenocarcinoma.
Xie M; Chen D; Li Y; Liu X; Kuang D; Li X
Diagn Pathol; 2022 Feb; 17(1):30. PubMed ID: 35172862
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.
Ko SJ; Lee YJ; Park JS; Cho YJ; Yoon HI; Chung JH; Kim TJ; Lee KW; Kim K; Jheon S; Kim H; Lee JH; Lee CT
BMC Cancer; 2014 May; 14():312. PubMed ID: 24885886
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype.
Kim H; Jang SJ; Chung DH; Yoo SB; Sun P; Jin Y; Nam KH; Paik JH; Chung JH
PLoS One; 2013; 8(10):e76999. PubMed ID: 24194854
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological and molecular features of pulmonary enteric adenocarcinoma].
Gao G; Wang YZ; Zhang YP; Feng SE; Hou M; Xia QX
Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):544-549. PubMed ID: 32486530
[No Abstract] [Full Text] [Related]
19. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
